This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


Interprotein Corporation
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/10/8
Profile

Delegates :
Masato HOSODA


Incorporated :
May   1 , 2001

Paid in Capital :
376 Million yen  

Employees :
9 人

Address :
I&F Umeda #704 3-10-2, Toyosaki, Kita-ku, Osaka OSAKA
〒531-0072

TEL/FAX :
+81-6-6374-5303 / +81-6-6374-5305

URL:
http://www.interprotein.com/

Attachment :

Mission/Background :
Interprotein Corporation is an Osaka University-originated biotech company that was established as Inter Cyto Nano Science Co., Ltd. in May, 2001, and the former name was changed into the present name in February, 2007. Interprotein is mainly conducting drug discovery researches for highly challenging targets such as protein-protein interactions (PPIs) with two platform technologies, INTENDD, an in silico drug design-based strategy for small molecule drug discovery, and helix-loop-helix peptide a conformationally constrained peptide. Regarding INTENDD, we are aiming at further technological innovation by introduction of artificial intelligence (AI). Based on the unique technologies, R&D staffs with a wealth of experience provide a solution to the “Death Valley”, which means the process of fundamental to practical stages or discovery to lead optimization stages, and contribute to raising the productivity of drug R&D.

Technology & Business
Interprotein is aiming at hit identification, lead generation and optimization for challenging drug targets including PPIs in collaboration with pharmaceutical companies. We are conducting in-house projects such as small molecule and/or peptide drug discovery researches for Runx1, an AML-related transcription factor (small molecule), TIM-3, an immune checkpoint (peptide), IL-6 (peptide and small molecule) and TNFalpha (small molecule) as well as new targets proposed by pharmaceutical companies. INTENDD (INTerprotein’s Engine for New Drug Design), a unique SBDD strategy established by Interprotein, will be applied for identification of new compounds with novel scaffolds. Interprotein also identifies novel peptide molecules that strongly bind to the targets using helix-loop-helix peptide technology. These approaches make it possible to conduct drug discovery researches in situations that no inhibitor information has been provided and crystal structure of the target protein has not been clarified.
Products & Service
Products & Service Name
Stage
Outline
Milestone
Small molecule Runx1 inhibitor
Discovery
We put a small molecule inhibitor for DNA binding of Runx1/CBFbeta to practical use as a new drug for acute myelocytic leukemia.
We form an alliance with a partner, and aim at hit validation and lead generation/optimization with the partner.
TIM-3 inhibitor (helix-loop-helix peptide)
Discovery
We focus on TIM-3, an immune checkpoint molecule and identify helix-loop helix peptides that bind to this target.
We form an alliance with a partner and aim at hit identification and lead generation/optimization with the partner.
TNFalpha inhibitor (small molecule)
Discovery
Small molecule modulators for TNFalpha/TNFalphaR interaction. We expect the broad applicability for many inflammatory diseases b
We form an alliance with a partner, and aim at hit validation and lead generation/optimization with the partner.
Small molecule drug discovery researches for new targets
Discovery
We conduct small molecule drug discovery researches for new targets proposed by pharmaceutical companies using INTENDD.
We form an alliance with a partner, and aim at hit identification and lead generation with the partner.
Peptide drug discovery researches for new targets
Discovery
We conduct peptide drug discovery researches for new targets proposed by pharmaceutical companies using helix-loop-helix peptide
We form an alliance with a partner, and aim at hit identification and lead generation with the partner.
Highlights
Interprotein conducted drug discovery researches with EA Pharma (former Ajinomoto Pharmaceuticals), Takeda Pharmaceutical, RaQualia Pharma and so on. As for Takeda's and RaQualia's cases, around 11% and 18% of the proposed compounds were recognized hit compounds, respectively. We also conducted in silico screening of Runx1-DNA binding inhibitors in collaboration with Yokohama City University and identified compounds that inhibit the binding with IC50 values of less than 1 microM and bind to Runx1.
Hot news
Interprotein Corporation and A.I. Squared, Inc. signed a joint research and development agreement for analysis of protein-protein interaction with artificial intelligence (AI) technology. Both companies will collaborate to develop unique novel pharmaceutical utilizing the expertise of Interprotein Corporation in molecular designing technologies and excellent AI technology including deep learning know-how of A.I. Squared, Inc. together for paradigm creation of new drug discovery.
Alliance strategy
Interprotein is seeking for alliance partners to advance current research programs (small molecule inhibitor for Runx1, peptide inhibitor for TIM-3, small peptide and/or small molecule inhibitors for IL-6, small molecule inhibitor for TNFalpha and so on). We also desire to conduct collaborative drug discovery researches aiming at identification of small molecules and/or helix-loop-helix peptides acting on various types of new drug targets.

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.